Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial
Journal
International journal of hematology
Journal Volume
114
Journal Issue
6
Pages
653 - 663
Date Issued
2021-12
Author(s)
Suzuki, Kenshi
Min, Chang-Ki
Kim, Kihyun
Lee, Je-Jung
Shibayama, Hirohiko
Ko, Po-Shen
Li, Sin-Syue
Ding, Bifeng
Khurana, Monica
Iida, Shinsuke
Abstract
Due to increasing use of frontline lenalidomide, effective and safe lenalidomide-free therapies for relapsed/refractory multiple myeloma (RRMM) are needed in Asia. This subgroup analysis of phase 3 CANDOR study evaluated efficacy and safety of KdD vs Kd in Asian patients with RRMM.
Subjects
Asian population; CANDOR trial; Carfilzomib; Daratumumab; Relapsed refractory multiple myeloma
SDGs
Publisher
SPRINGER JAPAN KK
Type
journal article